October 7, 2020
In 2015, researchers began noticing that a drug used to treat Type 2 diabetes, empagliflozin, came with the added benefit of decreasing hospitalization for heart failure and death from cardiovascular causes in those patients. “It was very unexpected, because this drug is targeted and marketed for Type 2 diabetes, not […]
